The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

Junjun Lu,1,* He Li,2,* Peng Guo,1 Rui Shen,3 Yingbin Luo,1 Qiao Ge,4 Wenfei Shi,1 Yan Li,1 Weikang Zhu1 1Department of Tumor, Shanghai Municipal Hospital of Traditional Chinese Medicine, 2Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, 3Department of Function, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 4Department of Tumor, Ninghai Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, China *These authors contributed equally to this work Objective: To evaluate the effect of CYP2D6 *10 polymorphism (C 100C>T, rs1065852) on clinical outcomes of female Asian breast cancer patients with tamoxifen adjuvant treatment.Methods: Meta-analysis of retrospective cohort studies published in July 2017 was performed. Fifteen studies with 1,794 Asian breast cancer patients were included, using strict eligibility requirements. Associations of disease-free survival (DFS), overall survival (OS) and recurrence rate after tamoxifen intake, with CYP2D6 *10 polymorphism were investigated through random effects models.Results: CYP2D6 *10 polymorphism was found to have effect on DFS and recurrence rate in various comparison models, but not on overall survival in the female Asian breast cancer patients.Conclusion: In conclusion, our meta-analysis suggests that significant association of *10/*10 (TT) genotype with poorer DFS and recurrence exists in female Asian breast cancer patients with tamoxifen 20 mg/day adjuvant treatment. In the future, large and well-designed studies are required to illustrate the interactions of CYP2D6 genetic variants, including *10 polymorphism and tamoxifen response on female breast cancer patients. Keywords: CYP2D6 *10, polymorphism, breast cancer, Asia, tamoxifen adjuvant treatment